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It is very easy to replace a faulty gene in an immunocompromised mouse. First, one takes
a well-characterized virus, such as an adenovirus or an adeno-associated virus, and incor-
porates the correct version of the faulty gene together with some regulatory sequences
into the genome. Then, one transduces the recombinant genome into helper cells, which
will add the viral capsid. At last, one injects the resulting viral vector into the sick mouse,
and the mouse is cured. It is not that easy in an immunocompetent mouse, let alone in
a human, as over the eons the immune system evolved to eliminate viruses regardless if
they penetrate as dangerous pathogens or are injected by a well-meaning gene therapist.
Here we offer our perspective on the potential of how viral vectors achieve sustained gene
transfer in the face of a hostile immune system.
Keywords: gene therapy
Gene therapy, which aims to temporarily or permanently replace
a faulty or missing protein at therapeutic levels, requires efﬁcient
transfer of genes into a host cell. The gene transfer vehicle has to
withstand enzymes in blood, ﬁnd the right cells, enter them and
then their nucleus. Viruses meet these criteria to the dot; their
capsids protect the genome, ensure that they enter cells and then
facilitate transfer of the gene into the nucleus.
Gene therapists have been attempting to take advantage of
viruses’ talents for gene transfer focusing on viruses that com-
monly infect humans.During themilleniums,well before primates
climbed down from trees evolution has selected for cellular organ-
isms that can ﬁght off viral infection ﬁrst through primitive innate
immune responses and then about 410 million years ago through
an adaptive immune system and its high speciﬁcity and abil-
ity to remember. Living beings have thus evolved for billions of
years to combat viruses. The evolution of gene therapy pales in
comparison; the ﬁrst humans were treated a mere 21 years ago.
Gene therapy can roughly be divided into two ﬁelds, transient
and permanent gene therapy. The latter can be divided into ex
and in vivo therapy. Transient or ex vivo gene transfers have their
own sets of problems, but the virtually insurmountable challenges
caused by anti-viral immune responses are mainly faced upon
direct injection of a viral vector for in vivo correction of a gene.
The two viral vectorsmost commonly used are based on adeno-
(Ad) and adeno-associated viruses (AAV).
Humans encounter different serotypes of Ad viruses early in
life and develop neutralizing antibodies. Prevalence rates of such
antibodies vary depending on the Ad serotype and the geographic
region (Chen et al., 2010). Neutralizing antibodies prevent the
virus from entering its target and thus reduce transduction rates.
This can be overcome, e.g., by using alternative Ad serotypes.
CD8+ T cells pose the bigger problem. Humans have robust
numbers of Ad virus-speciﬁc CD8+ T cells (Chen et al., 2010),
which are activated and are chock-full of granules containing lytic
enzymes (Hutnick et al., 2010). Even immunosuppression, short
of complete T cell ablation, would have no effect on the∼1 billion
Ad virus-speciﬁc CD8+ T cells of the average adult, which can
commence lysis immediately.
InAAVs vectored for use in gene therapy, theORFs are removed
and replaced with the gene of interest ﬂanked by the ITRs. Conver-
sion of the ssDNA genome of AAV vectors into double-stranded
(ds)DNA is rate limiting in transduction and delays onset of gene
expression (Ferrari et al., 1996). DsAAV vectors have been devel-
oped and shown to achieve per vector genome copy higher levels of
transgene product with accelerated onset of expression (McCarty
et al., 2001; Nathwani et al., 2006).
Prevalence rates of neutralizing antibodies to the different AAV
serotypes vary (Calcedo et al., 2009). Neutralizing antibodies, even
if present at only low titers, readily blocks AAV-mediated gene
transfer. Humans have circulating CD4+ and CD8+ T cells to
AAV capsid at low frequencies of approximately 0.1% of a given
subset. They less activated than those to Ad viruses and belong
predominantly to the effector memory or central memory subset
(Li et al., 2011).
Adeno-associated viruses-mediated gene transfer readily results
in sustained transgene expression in experimental animals (Song
et al., 1998;Mount et al., 2002;Gao et al., 2006) presumably reﬂect-
ing that AAV vectors are not particularly immunogenic. Based
on successes in animals, AAV vectors were tested in clinical gene
transfer trials. If given at moderate doses to an immunoprivi-
leged site, they resulted in some correction of disease (Maguire
et al., 2009). But if given systemically at the high doses needed
to encode beneﬁcial levels of a transgene product, such as factor
(F) IX in hemophilia B, ssAAV vectors induced a capsid-speciﬁc
CD8+ T cell response accompanied by loss of the therapeutic pro-
tein (Manno et al., 2006; Mingozzi et al., 2007). The potential
success of AAV-mediated gene transfer in humans may turn out
to be a numbers game. Transgene product expression by AAV vec-
tors with a dsDNA genome is more efﬁcient and in a recent trial
a dsAAV8 vector achieved near therapeutic levels of factor FIX in
hemophilia patients without evidence of T cell activation if given
at a dose of 2× 1010 vg/kg (Nathwani, 2010). In a preceding trial
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with ssAAV2 vectors for FIX, doses of 8× 1010 vg/kg failed to elicit
a T cell response but they also did not achieve detectable levels of
FIX. At the next tested dose of 4× 1011 vg/kg, T cell expansion was
observed although levels of FIX still remainedbelowdetection. FIX
levels together with increases in circulating AAV capsid-speciﬁc T
cells were not observed till the ﬁnal dose of 2× 1012 vg/kg (Manno
et al., 2006;Mingozzi et al., 2007). The T cell response to the capsid
proteins of AAV vectors is dictated by the input dose as without
de novo synthesis of capsid proteins, T cells rely on presentation
of degrading capsids, which are limiting both in terms of quantity
and duration. Assuming that AAV vector doses below∼1011 vg/kg
can dodge recognition by T cells, gene therapists should concen-
trate on the use of maximally efﬁcient AAV vectors. Nevertheless,
this assumption, which is based on low numbers of AAV vector
treated patients, has to be viewed with caution. Different serotypes
of AAV vectors or even ss versus dsAAV vectors may differ in the
degradation rate of their capsids. Processing of capsid for pre-
sentation of peptides with MHC class I molecules is mediated
by proteases, which in turn are upregulated by proinﬂammatory
cytokines. Capsids that are processed more rapidly may result in
a bolus of epitopes, which may favor T cell recognition unlike
capsids that are degraded slowly. Frequencies of circulating AAV
capsid-speciﬁc CD8+ T cells in humans vary and humans with
higher frequencies might be more prone to mount effective recall
responses to AAV gene transfer than humans with low frequen-
cies. Recommending ﬁrm doses for AAV-mediated gene transfer
will thus not be feasible till larger cohorts have been tested and one
can at this stage only advise a very conservative dose escalation.
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